 Shares of CureVac fell 42 in premarket trading on Thurdsay, a day after the German biotech said its COVID-19 vaccine was 47 effective in preventing the disease. CureVacs study, conducted in 10 countries and involving 40,000 people, showed the vaccines struggle against a fast changing environment of at least 29 COVID-19 variants, with the original coronavirus strain almost completely absent. 